LTRN Wutah bathi EPS kuartalan Lantern Pharma

Simbol resmi perusahaan Lantern (LTRN)

Lantern Pharma Inc. (LTRN) monetizes AI technologies by receiving payments for the development of personalized oncology drugs. The firm's strategy is based on expansion within the targeted therapy segment and the acceleration of LP-300 trials. Low geopolitical risks in the US ensure the stability of research. The current quarterly EPS growth value demonstrates profit dynamics, where -42.10 shows the value of this parameter on the chart.

Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan Lantern Pharma (LTRN): kanggo periode 04.07.2022 - 16.11.2026

LTRN (Lantern Pharma): rincian analitis lan laporan miturut indikator

- rega saham lan prakiraan rega para ahli:
Ringkesan analisis perusahaan:Lantern Pharma Inc, LTRN
Barang unggulan lanternpharma.com

For Lantern Pharma Inc. (LTRN), which utilizes machine learning to develop cancer therapies, the quarterly change in earnings per share reflects the efficiency of monetizing its intellectual databases. This indicator is calculated as the percentage deviation of the current EPS from the value of the same period last year, measuring the business's ability to generate real returns on capital and hedge against inflationary risks.